An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients
Status:
Withdrawn
Trial end date:
2020-02-19
Target enrollment:
Participant gender:
Summary
The hypothesis is that the treatment with ivabradine will increase pVO2 after 16 weeks of
treatment compared to baseline in the heart transplant recipient population with elevated
resting HR.